SEN and sensibility: interactions between newly discovered and other hepatitis viruses?
Di Bisceglie
A M
AM
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA. DIBISCAM@SLU.EDU
D000998:Antiviral Agents / Q000627:therapeutic use*; D004266:DNA Virus Infections / Q000150:complications* / Q000821:virology; D004267:DNA Viruses / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008107:Liver Diseases / Q000150:complications / Q000821:virology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin